Everand Logo

Welcome to Everand!

  • STAT

    Opinion: China isn’t yet ready to conduct clinical trials for the pharma industry

    by Anne Poli Aug 03, 2018 3 minutes
    Nearly all clinical research sites in China are hospitals. Because of that, clinical trial participants are treated exactly the same way as regular patients.

    China, with its huge population and its position as the second-largest pharmaceutical market in the world, should be poised to become a world leader in clinical trials for new drugs and devices. But it isn’t quite ready for that.

    Problems with protecting clinical trial participants, inadequate clinical trial infrastructure, and poor transparency make China an unreliable country in which to conduct a clinical trial. As a clinical research professional with more than a decade of global industry experience, I’ve seen

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT1 min read
    STAT+: No, Alcohol Isn’t Good For You. Will New Dietary Guidelines Be Shaped More By Health Or Industry Interests?
    More and more studies show that alcohol isn't healthy after all. Dietary guidelines are up for revision in 2025, and already, there's debate over research and industry influence.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT1 min read
    STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
    Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.

    Related Books & Audiobooks